News Details

The revised Implementation Regulations of the Drug Administration Law of the People’s Republic of China entered into force on May 15, 2026, under State Council Order No. 828. The updated regulatory framework strengthens China’s pharmaceutical supervision system by introducing stricter quality control, enhancing pharmacovigilance, and strengthening enforcement mechanisms throughout the entire drug lifecycle. 

Strengthened Drug Lifecycle Regulation Now in Effect 

The new regulations introduce an integrated supervision model covering drug development, registration, manufacturing, distribution, and post-market surveillance. 

Key regulatory features now implemented include: 

• Full lifecycle responsibility system for Marketing Authorization Holders (MAHs)  

• Enhanced supervision of drug research and clinical trial compliance  

• Strengthened drug registration and approval system under the National Medical Products Administration (NMPA)  

• Mandatory quality risk control for manufacturing and supply chain changes  

• Expanded traceability and compliance requirements  

Enhanced Drug R&D and Approval Pathways 

The revised framework further standardizes drug research and registration processes,  including accelerated pathways for innovative medicines. 

Key measures include: 

• Mandatory compliance with Good Laboratory Practice (GLP) and Good Clinical Practice (GCP)  

• A formalized qualification system for non-clinical safety evaluation institutions  

• Strengthened approval process managed by the National Medical Products Administration (NMPA)  

• Accelerated pathways such as priority review, conditional approval, breakthrough therapy, and special approval mechanisms  

• Improved regulatory framework for Traditional Chinese Medicines (TCM) development and approval  

Full Implementation of Pharmacovigilance System 

The revised regulations significantly strengthen post-market safety monitoring obligations. 

Requirements include: 

• Continuous adverse drug reaction monitoring by Marketing Authorization Holders  

• Mandatory periodic safety updates and risk-benefit evaluations  

• Regulatory authority to require post-market studies or impose product restrictions  

• Strengthened recall mechanisms and risk control obligations  

• Expanded coordination between healthcare institutions and regulatory authorities  

Manufacturing and Supply Chain Compliance Reinforced 

The updated system increases control over pharmaceutical manufacturing and distribution activities. 

Key requirements now implemented: 

• Strict licensing requirements for drug production and operation  

• Enhanced supervision of contract manufacturing arrangements  

• Prohibition or restriction of outsourcing for high-risk controlled substances  

• Mandatory traceability systems for drug products  

• Stricter control of production changes affecting product quality and safety  

Stronger Enforcement and Penalty Framework 

The enforcement system has been significantly strengthened under the new regulations. 

Key compliance risks include: 

• Fines of up to 10–20 times the value of illegal products in serious cases  

• Revocation or suspension of production and distribution licenses  

• A 10-year ban on reapplication for fraudulent regulatory submissions  

• Expanded inspection, seizure, and enforcement powers for regulators  

• Strict control of online pharmaceutical sales activities  

Regulatory Impact 

The implementation of the revised regulations signals a continued shift toward: 

• A risk-based and lifecycle regulatory system  

• Stronger accountability of pharmaceutical companies  

• Higher standards for drug safety and quality  

• Increased support for innovative and rare disease therapies  

• Further modernization of China’s pharmaceutical regulatory framework  

Effective Date 

The revised Implementation Regulations of the Drug Administration Law officially entered into force on May 15, 2026.